Track topics on Twitter Track topics that are important to you
SummaryIV Diagnostics Inc IV Diagnostics is a biomedical company that offers research services. The company conducts molecular diagnostic tests for circulating tumor cells and other blood borne diseases. It develops, tests and markets diagnostic tools that monitor and measure cancer tumor cells. IV Diagnostics' products include Velox, MagnoPraxis and Admonitrix. The company's Velox is used in trea...
SummaryThe Wistar Institute Wistar is a biomedical research institute that carries out medical research and training. The institute performs research in the areas of cancer, infectious diseases, immunology and vaccine development. It also conducts research on genes, gene expression, and DNA biology; cancer biology; translational research; and virology. Wistar develops vaccines against rotavirus, r...
Opinion: "Be better than your brain. If you love someone, get a flu shot." https://buff.ly/2Lkq46i
New #Cancer Drug Saves Teen's Life $LOXO https://www.nbcdfw.com/news/local/New-Cancer-Drug-Saves-Teens-Life-502818421.html …
SummaryVerisante Technology Inc Verisante is a medical device company that develops and commercializes systems for the early detection of cancer. The company's key product offerings include Verisante Aura, Verisante Core and Verisante MSI Camera. The Verisante Aura is used for skin cancer detection, and Verisante Core is used for lung, colon and cervical cancer detection. Verisante MSI Camera is a...
SummaryGeneNews Ltd GeneNews is a provider of molecular diagnostic products. The company develops and commercializes diagnostics and personalized medicine for cancer and other chronic diseases. Its Sentinel Principle is a novel approach to identifying biomarkers of body state using blood. GeneNews offers biomarkers for detect disease, stage diseases, monitor and progression and determine treatment...
Lethal combination: Drug cocktail turns off the juice to cancer cells https://www.unibas.ch/en/News-Events/News/Uni-Research/Drug-cocktail-turns-off-the-juice-to-cancer-cells.html …
Celltrion, $TEVA; FDA Approval of HERZUMA® a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications https://www.businesswire.com/news/home/20181214005566/en/Celltrion-Teva-Announce-FDA-Approval-HERZUMA%C
Celltrion, $TEVA; FDA Approval of HERZUMA® a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications https://www.businesswire.com/news/home/20181214005566/en/Celltrion-Teva-Announce-FDA-Approval-HERZUMA%C2%AE-trastuzumab-pkrb …
$BGNE Updated Phase 1A/1B Data on Tislelizumab Presented at #ESMO18 https://globenewswire.com/news-release/2018/12/15/1667574/0/en/BeiGene-Announces-Updated-Phase-1A-1B-Data-on-Tislelizumab-Presented-at-the-European-Society-for-Medical-Oncology-Immuno-Onc
$BGNE Updated Phase 1A/1B Data on Tislelizumab Presented at #ESMO18 https://globenewswire.com/news-release/2018/12/15/1667574/0/en/BeiGene-Announces-Updated-Phase-1A-1B-Data-on-Tislelizumab-Presented-at-the-European-Society-for-Medical-Oncology-Immuno-Oncology-Congress.html …
SummarySorrento Therapeutics Inc STI, formerly QuikByte Software Inc, is a cancer therapeutic service provider. The company offers CD38 CART, lidocaine topical system, resiniferatoxin. Its product pipeline includes CD38 CART, CEA CART, CD38 ADC and seprehvir. STI provides treatment for multiple myeloma, metastatic liver tumors and solid tumors. The company offers therapies for immune oncology, pai...
CAMBRIDGE, Mass. and BEIJING, China, Dec. 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced that updated clinical data from an ongoing Phase 1A/1B trial of tislelizumab, an investigational an...
Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved HERZUMA
Risk decreases over time with antireflux surgery or medication.
Research model relates variations in #DNA and gene activity to the risk of brain disorders: http://ow.ly/neer30mZrGK
Dr. Spyro Mousses, CEO of Systems Oncology, LLC, announced Systems Oncology’s diversified pipeline of innovative oncology programs discovered with the help of Artificial Intelligence at the AIMed North America Conference in Dana Point, California. Systems Oncology, an AI-based biopharmaceutical company, utilizes computational tools and machine l...
The FDA has approved trastuzumab-pkrb (Herzuma, Celltrion) as a biosimilar to trastuzumab (Herceptin, Genentech) for the treatment of HER2-overexpressing breast cancer.
Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, announced today that its rights offering has closed. The rights offering resulted in the issuance of 3,581,148 shares of the Company’s com...
NewsResearchers have keyed into the biological mishap that causes stunted brain growth and muscle movement failure.
SummaryCascadian Therapeutics Inc Cascadian, formerly Oncothyreon Inc is a clinicalstage biotechnology company that develops therapeutic products for the treatment of cancer. The company's lead clinicalstage product candidate includes ONT380, an orally active and selective smallmolecule HER2 inhibitor which is intended for the treatment of HER2positive HER2+ metastatic breast cancer. It also devel...
Time-dependent analysis confirms that the answer is no.
Tens of millions of baby boomers are expected to live long enough to develop Alzheimer’s, and just about as many are worried about those prospects. One of them is a writer on Cape Cod named Susan Moeller. A recent memory lapse prompted her to publish her hopes, fears and observations.
A far-out theory proposed earlier this year falls apart under closer examination, says a new study.
NewsThe licensing agreement for the HD20 trastuzumab biosimilar gives Cipla Ltd. exclusive rights to distribute and market the drug in selected emerging markets.
CT-P6, a proposed biosimilar to trastuzumab, exhibited long-term disease-free survival and overall survival similar to the reference product in the treatment of patients with HER2-positive early breast cancer.
Terumo Corporation Strategy, SWOT and Corporate Finance ReportSummaryTerumo Corporation Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.Key HighlightsTerumo Corporation Terumo or 'the ...